Switching Lamotrigine from Extended-Release to Immediate-Release
You can directly switch from lamotrigine extended-release (ER) to immediate-release (IR) formulation using the same total daily dose without any adjustment period. 1, 2
Dosing Conversion Strategy
- Convert 1:1 (same total daily dose) when switching from ER to IR formulation 1, 2
- The bioequivalence studies demonstrate that ER and IR formulations are equivalent with respect to steady-state area under the curve (AUC), trough concentrations, and average concentrations 1, 2
- Split the total daily ER dose into twice-daily IR dosing (e.g., 300 mg ER once daily becomes 150 mg IR twice daily) 2
Pharmacokinetic Considerations
The key differences you'll observe after conversion include:
- Peak concentrations (Cmax) will be approximately 15% higher with IR compared to ER formulation 1
- Time to peak concentration (Tmax) will be faster with IR (1-1.5 hours) versus ER (3-11 hours depending on concomitant medications) 2
- Peak-to-trough fluctuation will increase by approximately 33% with IR formulation 1
- Trough concentrations remain similar between formulations, which is why the same total daily dose maintains therapeutic efficacy 2
Impact of Concomitant Medications
The conversion is straightforward across all metabolic groups:
- Enzyme-inducing AEDs (phenytoin, carbamazepine): Use same total daily dose 2
- Metabolically neutral AEDs: Use same total daily dose 2
- Enzyme-inhibiting AEDs (valproate): Use same total daily dose 2
One caveat: In patients taking enzyme-inducing AEDs, the ER formulation showed a 21% lower AUC compared to IR in one study, but trough concentrations remained equivalent, supporting the same total daily dose conversion 2
Clinical Implications of the Switch
- Patients may experience more peak-related adverse effects (dizziness, blurred vision, diplopia, unsteadiness) with IR due to higher peak concentrations 3
- Seizure control should remain stable as trough levels are maintained 2
- Consider therapeutic drug monitoring if the patient was previously experiencing breakthrough seizures on ER, as the higher peaks with IR might provide better coverage 3
Common Pitfalls to Avoid
- Do not reduce the total daily dose when converting from ER to IR—the formulations are bioequivalent at the same total daily dose 1, 2
- Do not attempt a gradual crossover—direct substitution is appropriate 1, 2
- Monitor for peak-related side effects in the first few weeks after conversion, as the 15% higher Cmax may cause tolerability issues in some patients 1